Trial Profile

A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obicetrapib (Primary)
Indications Dyslipidaemias; Hypercholesterolaemia
Focus Therapeutic Use
Sponsors NewAmsterdam Pharma

Most Recent Events

07 May 2025 According to NewAmsterdam Pharma media release, data from the study were presented at European Atherosclerosis Society (EAS) Congress 2025.
13 Nov 2023 According to NewAmsterdam Pharma media release, previously reported data from this trial presented at the American Heart Association (AHA) Scientific Sessions in November 2023.
05 Sep 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com